/PRNewswire/ Ellipses Pharma Limited ("Ellipses"), a global drug development company focused on accelerating the development of cancer treatments through an.
Ellipses Pharma: Ellipses next generation selective RET inhibitor EP0031/A400 cleared to start Phase 2 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Next-Gen PARP Inhibitor Shows Benefit in Breast Cancer Patients miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.